U.S., Sept. 5 -- ClinicalTrials.gov registry received information related to the study (NCT07155226) titled 'Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression' on Aug. 14.
Brief Summary: The purpose of this study is to understand the safety, tolerability, efficacy, pharmacokinetic (PK), pharmacodynamic (PD), and preliminary efficacy of orally administered AZD3632 in participants with advanced haematologic malignancies with KMT2Ar, NPM1m, or other genotypes associated with homeobox (HOX) overexpression.
Study Start Date: Nov. 03
Study Type: INTERVENTIONAL
Condition:
Acute Lymphoblastic Leu...